How to buy 10x Genomics stock | $161.61

10x Genomics Inc is a health information services business based in the US. 10x Genomics shares (TXG) are listed on the NASDAQ and all prices are listed in US Dollars. 10x Genomics employs 1,053 staff and has a trailing 12-month revenue of around 0.00.

10x Genomics stock price (NASDAQ: TXG)

Use our graph to track the performance of TXG stocks over time.

10x Genomics shares at a glance

• Key figures

Information last updated 2021-10-16.

Latest market close	$161.61
52-week range	$125.84 - $208.99
50-day moving average	$161.54
200-day moving average	$174.27
Wall St. target price	$192.78
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-4.72

Buy 10x Genomics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy 10x Genomics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

10x Genomics price performance over time

Historical closes compared with the close of $161.61 from 2021-10-20

1 week (2021-10-14)	5.13%
1 month (2021-09-21)	0.39%
3 months (2021-07-21)	-12.20%
6 months (2021-04-21)	-13.83%

1 year (2020-10-21)	13.01%
2 years (2019-10-21)	202.87%
3 years (2018-10-17)	N/A
5 years (2016-10-17)	N/A

Is 10x Genomics under- or over-valued?

Valuing 10x Genomics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of 10x Genomics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

10x Genomics's EBITDA

10x Genomics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $10.1 million.

The EBITDA is a measure of a 10x Genomics's overall financial performance and is widely used to measure a its profitability.

10x Genomics financials

Revenue TTM	$405.7 million
Gross profit TTM	$249.9 million
Return on assets TTM	-3.95%
Return on equity TTM	-85.73%
Profit margin	-124.24%
Book value	$7.09
Market capitalisation	$17 billion

TTM: trailing 12 months

Shorting 10x Genomics shares

There are currently 3.4 million 10x Genomics shares held short by investors – that's known as 10x Genomics's "short interest". This figure is 1.9% down from 3.5 million last month.

There are a few different ways that this level of interest in shorting 10x Genomics shares can be evaluated.

10x Genomics's "short interest ratio" (SIR)

10x Genomics's "short interest ratio" (SIR) is the quantity of 10x Genomics shares currently shorted divided by the average quantity of 10x Genomics shares traded daily (recently around 673419.20792079). 10x Genomics's SIR currently stands at 5.05. In other words for every 100,000 10x Genomics shares traded daily on the market, roughly 5050 shares are currently held short.

However 10x Genomics's short interest can also be evaluated against the total number of 10x Genomics shares, or, against the total number of tradable 10x Genomics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case 10x Genomics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 10x Genomics shares in existence, roughly 30 shares are currently held short) or 0.0394% of the tradable shares (for every 100,000 tradable 10x Genomics shares, roughly 39 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against 10x Genomics.

Find out more about how you can short 10x Genomics stock.

10x Genomics share dividends

We're not expecting 10x Genomics to pay a dividend over the next 12 months.

Have 10x Genomics's shares ever split?

10x Genomics's shares were split on a 1:2 basis on 16 July 2006. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your 10x Genomics shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for 10x Genomics shares which in turn could have impacted 10x Genomics's share price.

10x Genomics share price volatility

Over the last 12 months, 10x Genomics's shares have ranged in value from as little as $125.84 up to $208.99. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while 10x Genomics's is 1.41. This would suggest that 10x Genomics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

10x Genomics overview

10x Genomics, Inc. , a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc.

Frequently asked questions

What percentage of 10x Genomics is owned by insiders or institutions?
Currently 2.066% of 10x Genomics shares are held by insiders and 89.013% by institutions. How many people work for 10x Genomics?
Latest data suggests 1,053 work at 10x Genomics. When does the fiscal year end for 10x Genomics?
10x Genomics's fiscal year ends in December. Where is 10x Genomics based?
10x Genomics's address is: 6230 Stoneridge Mall Road, Pleasanton, CA, United States, 94588 What is 10x Genomics's ISIN number?
10x Genomics's international securities identification number is: US88025U1097 What is 10x Genomics's CUSIP number?
10x Genomics's Committee on Uniform Securities Identification Procedures number is: 88025U109